(Q39051661)

English

Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts

scientific article published on December 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts (English)

1 reference

Europe PubMed Central

8 September 2017

1 reference

based on heuristic

inferred from title

author name string

Soomin Yoon

1

1 reference

Europe PubMed Central

8 September 2017

Yun-Hee Kim

2

1 reference

Europe PubMed Central

8 September 2017

Se Hun Kang

3

1 reference

Europe PubMed Central

8 September 2017

Seok-Ki Kim

4

1 reference

Europe PubMed Central

8 September 2017

Hwa Kyoung Lee

5

1 reference

Europe PubMed Central

8 September 2017

Hyori Kim

6

1 reference

Europe PubMed Central

8 September 2017

Junho Chung

7

1 reference

Europe PubMed Central

8 September 2017

In-Hoo Kim

8

1 reference

Europe PubMed Central

8 September 2017

publication date

1 December 2013

1 reference

Europe PubMed Central

8 September 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

8 September 2017

140

1 reference

Europe PubMed Central

8 September 2017

2

1 reference

Europe PubMed Central

8 September 2017

227-233

1 reference

Europe PubMed Central

8 September 2017

https://scigraph.springernature.com/pub.10.1007/s00432-013-1548-4

0 references

Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

A validated method for the determination of nicotine, cotinine, trans-3'-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Antibody-targeted radiation cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

A sensitive enzyme immunoassay for measuring cotinine in passive smokers

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Cotinine-conjugated aptamer/anti-cotinine antibody complexes as a novel affinity unit for use in biological assays

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Evidence that nicotine acetylcholine receptors are not the main targets of cotinine toxicity.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1548-4

21 January 2018

Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretargeted radioimmunotherapy of cancer: progress step by step

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity in rabbits and mice of an antibody-chelate conjugate: comparison of (S) and (R) macrocyclic enantiomers and an acyclic chelating agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Göttingen/Marburg experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Three-step immunoscintigraphy with anti-chromogranin A monoclonal antibody in tumours of the pituitary region

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies on the metabolism of (-)-cotinine in the human

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AUR Memorial Award 1991. Immunogenicity of gadolinium-based contrast agents for magnetic resonance imaging. Induction and characterization of antibodies in animals

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detailed Toxicity Studies of Liposomal Gadolinium-DTPA

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24292501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-013-1548-4

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39051661&oldid=1806043400"